GYRE · Gyre Therapeutics, Inc. · Executive Compensation
$6.76
-0.28 (-3.98%)
At close · Oct 8
Return incl. dividend (before tax)
Market Cap
$753.81M
Shares
111.51M
Volume · Oct 8
82.84K
Avg daily vol (3M)
105.28K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Weiguo Ye | Chief Operating Officer | $5,023,749 |
| Ping Zhang | Interim Chief Executive Officer | $4,096,623 |
| Han Ying | Senior Vice President, Science and Former Chief Executive Officer | $353,315 |
| Ruoyu Chen | Chief Financial Officer | $285,583 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Han Ying | Chief Executive Officer | $2,888,140 |
| Ruoyu Chen | Chief Financial Officer | $650,516 |
| Weiguo Ye | Chief Operating Officer | $332,619 |
| Charles Wu | Former Chief Executive Officer | $15,350 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Weiguo Ye | Chief Operating Officer | $274,617 |
| Ruoyu Chen | Chief Financial Officer | $208,162 |
| Charles Wu | Former Chief Executive Officer | $106,152 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Charles Wu | Chief Executive Officer | $78,347 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Nassim Usman | President and Chief Executive Officer Clinton ^^ Musil Chief Financial Officer | $1,409,622 |
| Howard Levy | M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | $826,709 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Nassim Usman | President and Chief Executive Officer Clinton ^^ Musil Chief Financial Officer | $1,198,865 |
| Howard Levy | M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | $733,018 |
| Fletcher Payne | Former Chief Financial Officer | $471,208 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Nassim Usman | President and Chief Executive Officer | $2,442,314 |
| Howard Levy | M.B.B.Ch., Ph.D., M.M.M Chief Medical Officer | $1,198,847 |
| Fletcher Payne | Former Chief Financial Officer | $969,476 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Claire Weston, Ph.D. | Class III director | Appointed | 2026-07-16 |
| Maxwell Kirkby | Class II director | Appointed | 2026-07-16 |
| Yue Xiong, Ph.D. | Class I director | Appointed | 2026-07-16 |
| Thomas Eastling | Chief Financial Officer of the Company | Appointed | 2026-05-04 |
| Ruoyu Chen | Chief Financial Officer | Resigned | 2026-05-04 |
| Ying Luo | Board as a Class I director | Appointed | 2026-05-04 |
| Ying Luo | Chief Executive Officer and President of the Company | Appointed | 2026-05-04 |
| Songjiang Ma | President of the Company | Resigned | 2026-05-04 |
| Songjiang Ma | board of directors of the Company | Resigned | 2026-05-04 |
| Thomas Eastling | board of directors of the Company | Resigned | 2026-05-04 |
| Ying Luo | member of the board of directors | Appointed | 2026-03-02 |
| Ying Luo | President and Chief Executive Officer | Appointed | 2026-03-02 |
| Ying Luo, Ph.D. | Class I director | Appointed | 2026-03-02 |
| Ying Luo, Ph.D. | Chief Executive Officer and President of the Company | Appointed | 2026-03-02 |
| Songjiang Ma | President of the Company | Resigned | 2026-03-02 |
| Songjiang Ma | Board | Resigned | 2026-03-02 |
| Thomas Eastling | Board | Resigned | 2026-03-02 |
| Dan Weng, M.D. | Class II director | Appointed | 2025-08-22 |
| Han Ying | member of the Board | Resigned | 2025-08-11 |
| Han Ying | Chief Executive Officer | Resigned | 2025-08-11 |
| Ping Zhang | Interim Chief Executive Officer | Appointed | 2025-08-11 |
| Songjiang Ma | Chairman of the Gyre Pharmaceuticals Board | Appointed | 2025-01-06 |
| Ping Zhang | Class I director | Appointed | 2025-01-06 |
| Ying Luo | Chairman and a member of the board of directors | Resigned | 2025-01-06 |
| David Epstein, Ph.D. | Class II director | Appointed | 2024-08-08 |